Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Treatment-naive children under 18 with Crohn's disease (80), ulcerative colitis (27), non-IBD gastrointestinal symptoms (50), and healthy controls (75) had fecal microbiota profiled. The goal was diagnosis, phenotyping, and predicting need for biologic therapy.
How was it studied?
A targeted qPCR platform (Bio-Me PMP) quantified over 100 bacterial species and sub-species in fecal samples at diagnosis, before any treatment. Diagnostic, Phenotype, and Prognostic Indexes were built from species whose abundance differed significantly between groups.
What did they find?
Beneficial bacterial species were reduced in IBD and non-IBD patients compared to healthy children, with IBD patients most affected. Crohn's disease patients had lower Bifidobacterium abundance than ulcerative colitis patients, and patients later needing biologic therapy had lower abundance of butyrate-producing bacteria at diagnosis. A high Diagnostic Index gave 2.5 times higher odds of having IBD, and a high Prognostic Index gave 2.1 times higher odds of needing biologic therapy.
Why it matters
Fecal bacterial abundance measured before treatment could help distinguish Crohn's disease from ulcerative colitis and flag children likely to need biologic therapy, without invasive testing.